Regeneron Announces Updates to Board of Directors
08 sept. 2023 16h45 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron’s...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
15 août 2023 15h40 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
09 août 2023 07h30 HE
|
Regeneron Pharmaceuticals, Inc.; Decibel Therapeutics, Inc.
Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational...
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
01 août 2023 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a...
Regeneron Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
25 juil. 2023 15h04 HE
|
Block & Leviton LLP
BOSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for potential securities law violations. Investors who have lost money...
REGN Shareholder News: Johnson Fistel Encourages Regeneron Pharmaceuticals Shareholders with Losses to Contact the Firm Regarding Investigation
30 juin 2023 14h49 HE
|
Johnson Fistel, LLP
SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the...
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
25 mai 2023 17h00 HE
|
Regeneron Pharmaceuticals, Inc.
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar...
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
19 mai 2023 12h54 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and WASHINGTON, D.C., May 19, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Kaitlyn Wang, 17,...
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
29 mars 2023 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday...
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
22 mars 2023 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol...